Recently, the aberrant expression of CYTOR has been reported in some types of cancers including gastric cancer [12], hepatocellular carcinoma [13], colon cancer [14], gallbladder cancer [15] and renal cell carcinoma [16], in which it may act as an oncogene. Here, CYTOR is linked to renal cell carcinoma.